- N-Ethyl-N,6-dimethyl-9,10-didehydroergoline-8β-carboxamide
- (6aR,9R)-N-Ethyl-N,7-dimethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
- (8β)-N-Ethyl-N,6-dimethyl-9,10-didehydroergoline-8-carboxamide
Shulgin, AT. Chemistry of psychotomimetics In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 928 kB. https://doi.org/10.1007/978-3-642-67770-0_1 #8p
Shulgin, AT. Basic Pharmacology and Effects In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Shulgin, AT. Hallucinogens In Burger’s Medicinal Chemistry, 4th ed., Part III; Wolff, ME, Ed., John Wiley & Sons, Inc., 1 Jan 1981; pp 1109–1137. 4.7 MB. #34k
Shulgin, AT. Psychotomimetic agents In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, 1 Jan 1976; Vol. 4, pp 59–146. 3.1 MB.
Oberlender, RA. Stereoselective aspects of hallucinogenic drug action and drug discrimination studies of entactogens Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 May 1989. 8.2 MB. MS,NMR,IR,other
Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB. #Table 2 (R1=CH3, R2=CH2CH3)